AUSTIN, Texas, May 30, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. AGLE, a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, today announced that Anthony G. Quinn, M.B. Ch.B, Ph.D., president and chief executive officer of Aeglea, will participate in the following investor and industry conferences in June.
Jefferies 2019 Healthcare Conference
Date: Wednesday, June 5, 2019
Presentation Time: 8:30 a.m. ET
Location: New York, NY
Webcast: http://ir.aegleabio.com/events-and-presentations/upcoming-events
BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference
Date: Tuesday, June 25, 2019
Presentation Time: 11:40 a.m. ET
Location: New York, NY
Webcast: http://ir.aegleabio.com/events-and-presentations/upcoming-events
BIO International Convention
Date: Tuesday, June 4, 2019
Presentation Time: 3:15 p.m. ET
Location: Philadelphia, PA
About Aeglea BioTherapeutics
Aeglea is a clinical-stage biotechnology company that engineers next generation human enzymes with enhanced properties and novel activity to provide solutions for diseases with unmet medical need. Aeglea is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency and in combination with an immune checkpoint inhibitor for small cell lung cancer. In addition, Aeglea has an active pipeline of other human enzyme-based approaches including programs for both Homocystinuria and Cystinuria. For more information, please visit http://aegleabio.com.
Media Contact:
David Calusdian
Sharon Merrill Associates
617.542.5300
AGLE@investorrelations.com
Investor Contact:
Joey Perrone
Senior Director, Finance & Investor Relations
Aeglea BioTherapeutics
investors@aegleabio.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
